abstract |
The present invention is based, at least in part, on the discovery that PDK1 is associated with the outer plasma membrane of the cell. Accordingly, the present invention encompasses 3-phosphoinositide-dependent protein kinase-1 (PDK1) binding molecules, such as an antibody. The binding molecules of the invention are useful for detecting PDK1 and for inhibiting PDK1 activity, e.g., in a human subject having a disorder in which PDK1 activity is detrimental, such as a cancer. |